SCHEMBL2308673

SCHEMBL2308673

COc1ccc2c(C)n[nH]c(=O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.59
PDE4B Q07343 1/20 0.50
ENPP1 P22413 1/20 0.49
KDM4E B2RXH2 3/20 0.49
HSD17B10 Q99714 2/20 0.49
LMNA P02545 1/20 0.49
PIK3R1 P27986 5/20 0.47
PIK3CA P42336 5/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
DRD1 P21728 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
PARP15 Q460N3 1/20 0.43
PARP14 Q460N5 1/20 0.43
PARP10 Q53GL7 1/20 0.43
TNKS2 Q9H2K2 1/20 0.43
PARP2 Q9UGN5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2305371 0.93 DYRK1A (0.59) DYRK1APDE4BENPP1KDM4EHSD17B10
SCHEMBL4124300 0.81 ENPP1 (0.66) DYRK1APDE4BENPP1KDM4EPIK3CA
SCHEMBL4844032 0.80 ENPP1 (0.62) DYRK1APDE4BENPP1KDM4ELMNA
SCHEMBL4834510 0.80 ENPP1 (0.58) DYRK1APDE4BENPP1KDM4EPIK3CA
SCHEMBL4117496 0.80 GAA (0.51) DYRK1APDE4BENPP1KDM4EHSD17B10
SCHEMBL25839255 0.79 CHEK1 (0.44) DYRK1ALMNADRD1ALDH1A1
SCHEMBL4131883 0.78 GAA (0.50) DYRK1APDE4BENPP1KDM4EHSD17B10
SCHEMBL4843618 0.78 GSK3A (0.65) DYRK1APDE4BENPP1KDM4EPIK3CA
SCHEMBL11170339 0.78 PRKAG1 (0.56) DYRK1APDE4BENPP1KDM4EHSD17B10
SCHEMBL4134456 0.78 PIK3CA (0.47) DYRK1APDE4BENPP1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 CN disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
EP-4076418-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115135315-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2022-09-30 CN disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 DYRK1A 3243/4885PDE4B 3016/4885ENPP1 373/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 DYRK1A 3243/4885PDE4B 3016/4885ENPP1 373/4885
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 DYRK1A 4800/4885PDE4B 1845/4885ENPP1 661/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 DYRK1A 3243/4885PDE4B 3016/4885ENPP1 373/4885
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AGTR1, AGTR2, AHR DYRK1A 2933/4885PDE4B 1459/4885ENPP1 2915/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST DYRK1A 2916/4885PDE4B 2015/4885ENPP1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.